Enodia Therapeutics Acquires Kezar's Sec61-Based Assets, Enhancing Insights into Targeted Protein Degradation.

Enodia Therapeutics has acquired preclinical assets from Kezar Life Sciences to strengthen its Sec61 portfolio. The acquisition provides Enodia with insights into Sec61 selectivity for targeted protein degradation, supporting accelerated development of its novel small-molecule inhibitors. Enodia will receive an upfront payment of $1 million and potential future payments of up to $127 million, plus royalties on net sales. The acquisition enhances Enodia's ability to make informed development decisions across its candidate programs.